DK0626447T3 - Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen - Google Patents

Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen

Info

Publication number
DK0626447T3
DK0626447T3 DK94108104T DK94108104T DK0626447T3 DK 0626447 T3 DK0626447 T3 DK 0626447T3 DK 94108104 T DK94108104 T DK 94108104T DK 94108104 T DK94108104 T DK 94108104T DK 0626447 T3 DK0626447 T3 DK 0626447T3
Authority
DK
Denmark
Prior art keywords
sfv
hiv
monoclonal antibody
cells
antigen
Prior art date
Application number
DK94108104T
Other languages
English (en)
Inventor
Michael L Diegel
Peter S Linsley
Lisa K Gilliland
Joyce M Zarling
Patricia A Moran
Jeffrey A Ledbetter
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK0626447T3 publication Critical patent/DK0626447T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK94108104T 1993-05-25 1994-05-25 Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen DK0626447T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/068,946 US5795572A (en) 1993-05-25 1993-05-25 Monoclonal antibodies and FV specific for CD2 antigen

Publications (1)

Publication Number Publication Date
DK0626447T3 true DK0626447T3 (da) 2006-02-20

Family

ID=22085730

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94108104T DK0626447T3 (da) 1993-05-25 1994-05-25 Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen

Country Status (8)

Country Link
US (3) US5795572A (da)
EP (1) EP0626447B1 (da)
JP (1) JP3863196B2 (da)
AT (1) ATE305971T1 (da)
CA (1) CA2124126C (da)
DE (1) DE69434499T2 (da)
DK (1) DK0626447T3 (da)
ES (1) ES2249759T3 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
NZ510831A (en) * 1998-08-31 2002-12-20 Biogen Inc Method of modulating memory effector T-cells and compositions
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) * 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
EP2706116A1 (en) * 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
AU2002320352A1 (en) 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP1718329A4 (en) * 2004-02-06 2008-09-10 Astellas Us Llc METHOD FOR THE TREATMENT OF SKIN DISEASES
EP1747291A2 (en) * 2004-05-04 2007-01-31 Genaissance Pharmaceuticals, Inc. Haplotype markers and methods of using the same to determine response to treatment
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
RU2393872C2 (ru) * 2004-08-30 2010-07-10 Шеринг Акциенгезельшафт Лечение вич инфекции посредством т-клеточной модуляции
NI200800032A (es) 2005-07-25 2009-03-23 Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
SI2132228T1 (sl) * 2008-04-11 2011-10-28 Emergent Product Dev Seatle CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US11820807B2 (en) * 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
CN107835693B (zh) * 2015-06-12 2021-11-02 联亚药业股份有限公司 免疫球蛋白融合蛋白及其用途
KR102440820B1 (ko) 2015-09-08 2022-09-05 테리피온, 인크. ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2019075125A1 (en) 2017-10-11 2019-04-18 Yuntao Wu COMPOSITIONS AND METHODS OF USING CD2-INITIATED SIGNALING PATHWAYS TO BLOCK HIV INFECTION
EA202090922A1 (ru) * 2017-11-29 2021-03-09 Маджента Терапьютикс, Инк. Композиции и способы истощения cd2+ клеток
EP3958908A1 (en) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
WO2020236795A2 (en) 2019-05-21 2020-11-26 Novartis Ag Trispecific binding molecules against bcma and uses thereof
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
CN114206940B (zh) * 2019-07-23 2023-09-22 南京金斯瑞生物科技有限公司 抗cd47/抗lag-3双特异抗体及其制备方法和应用
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009344A1 (en) * 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
CA2049931A1 (en) * 1990-01-24 1991-07-25 Barbara P. Wallner Lfa-3 as a vaccine adjuvant
US5629162A (en) * 1991-06-11 1997-05-13 The Center For Blood Research Method of identifying agents which modulate ICAM-3 binding to LFA-1
DE69223638T2 (de) * 1991-10-07 1998-05-20 Biogen Inc Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung

Also Published As

Publication number Publication date
ATE305971T1 (de) 2005-10-15
EP0626447B1 (en) 2005-10-05
CA2124126C (en) 2007-10-16
DE69434499D1 (de) 2006-02-16
US5795572A (en) 1998-08-18
JPH07147983A (ja) 1995-06-13
US6384198B1 (en) 2002-05-07
EP0626447A1 (en) 1994-11-30
JP3863196B2 (ja) 2006-12-27
DE69434499T2 (de) 2006-06-22
US5807734A (en) 1998-09-15
ES2249759T3 (es) 2006-04-01
CA2124126A1 (en) 1994-11-26

Similar Documents

Publication Publication Date Title
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
AU2349697A (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon
DE19975033I2 (de) CD25-bindende Molek}le
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
PT1042492E (pt) Anticorpos monoclonais humanizados que protegem contra doença induzida pela toxina shiga
AU3095892A (en) Human type antibody reactive with GPIIb/IIIa
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
EP0725081A4 (en) MONOCLONAL ANTIBODIES AGAINST MxA OF Mx PROTEIN OF MAN
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
ATE490271T1 (de) Rezeptor, dessen verwendung sowie mausantikörper
JPS6461499A (en) Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
EP0554670A3 (en) Specific antibodies against activated platelets, their production and applications in diagnostics and therapeutics
ATE110786T1 (de) Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa.
BG51639A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome